JP2009544628A - 外傷治療 - Google Patents

外傷治療 Download PDF

Info

Publication number
JP2009544628A
JP2009544628A JP2009521065A JP2009521065A JP2009544628A JP 2009544628 A JP2009544628 A JP 2009544628A JP 2009521065 A JP2009521065 A JP 2009521065A JP 2009521065 A JP2009521065 A JP 2009521065A JP 2009544628 A JP2009544628 A JP 2009544628A
Authority
JP
Japan
Prior art keywords
adenosine
heart
composition
lignocaine
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009521065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544628A5 (enExample
Inventor
ジェフリー フィリップ ドブソン，
Original Assignee
ハイバーネイション セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006904007A external-priority patent/AU2006904007A0/en
Application filed by ハイバーネイション セラピューティクス リミテッド filed Critical ハイバーネイション セラピューティクス リミテッド
Publication of JP2009544628A publication Critical patent/JP2009544628A/ja
Publication of JP2009544628A5 publication Critical patent/JP2009544628A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
JP2009521065A 2006-07-25 2007-07-25 外傷治療 Withdrawn JP2009544628A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2006904007A AU2006904007A0 (en) 2006-07-25 Trauma Therapy
AU2007900283A AU2007900283A0 (en) 2007-01-19 Trauma therapy (II)
PCT/AU2007/001029 WO2008011670A1 (en) 2006-07-25 2007-07-25 Trauma therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013247231A Division JP5833618B2 (ja) 2006-07-25 2013-11-29 外傷治療

Publications (2)

Publication Number Publication Date
JP2009544628A true JP2009544628A (ja) 2009-12-17
JP2009544628A5 JP2009544628A5 (enExample) 2014-01-30

Family

ID=38981058

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009521065A Withdrawn JP2009544628A (ja) 2006-07-25 2007-07-25 外傷治療
JP2013247231A Expired - Fee Related JP5833618B2 (ja) 2006-07-25 2013-11-29 外傷治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013247231A Expired - Fee Related JP5833618B2 (ja) 2006-07-25 2013-11-29 外傷治療

Country Status (12)

Country Link
US (3) US20090324748A1 (enExample)
EP (1) EP2139316B1 (enExample)
JP (2) JP2009544628A (enExample)
KR (2) KR20140108346A (enExample)
CN (2) CN101516185A (enExample)
AU (1) AU2007278754B2 (enExample)
CA (1) CA2692256C (enExample)
ES (1) ES2539762T3 (enExample)
IL (1) IL196702A0 (enExample)
SG (1) SG173404A1 (enExample)
WO (1) WO2008011670A1 (enExample)
ZA (1) ZA200901376B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE361667T1 (de) 1999-03-23 2007-06-15 Hibernation Therapeutics Ltd Stoppen, schützen und konservieren von organen
KR101425579B1 (ko) 2006-05-29 2014-08-13 하이버네이션 테라퓨틱스 리미티드 개선된 조직 유지법
EP2139316B1 (en) 2006-07-25 2015-03-18 Hibernation Therapeutics, a KF LLC Trauma therapy
WO2008070741A1 (en) * 2006-12-06 2008-06-12 Ikaria, Inc. Compositions and methods for enhancing survival and reducing injury under ischemic or hypoxic conditions
US7717855B2 (en) * 2006-12-06 2010-05-18 The Hospital For Sick Children System for performing remote ischemic preconditioning
US20100119554A1 (en) 2007-03-02 2010-05-13 Hibernation Therapeutics Limited Transplants
US7754247B2 (en) 2007-05-29 2010-07-13 University Of South Carolina Resuscitation fluid
JP2010534208A (ja) * 2007-07-25 2010-11-04 ハイバーネイション セラピューティクス リミテッド 改善された臓器の保護、保存および回復
EP2384198A4 (en) * 2008-12-30 2012-08-08 Endogenx Inc PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL INJURIES
ES2431013T3 (es) * 2009-05-13 2013-11-22 The Hospital For Sick Children Potenciación del rendimiento
JP2013518618A (ja) * 2010-02-01 2013-05-23 ザ・ホスピタル・フォー・シック・チルドレン 再狭窄を治療および予防するための遠隔虚血コンディショニング
CA2795053A1 (en) 2010-03-31 2011-10-06 The Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
CN103354733B (zh) 2010-04-08 2017-02-22 儿童医院 用于外伤性损伤的远端缺血处理的用途
US8764789B2 (en) 2011-04-15 2014-07-01 CellAegis Devices Inc. System for performing remote ischemic conditioning
USD708338S1 (en) 2012-08-15 2014-07-01 CellAegis Devices Inc. Cuff for remote ischemic conditioning
WO2014167423A2 (en) 2013-03-15 2014-10-16 The Hospital For Sick Children Methods for modulating autophagy using remote ischemic conditioning
WO2014140832A2 (en) 2013-03-15 2014-09-18 The Hospital For Sick Children Treatment of erectile dysfunction using remote ischemic conditioning
CA2904162A1 (en) 2013-03-15 2014-12-18 The Hospital For Sick Children Methods relating to the use of remote ischemic conditioning
AU2013203746B2 (en) 2013-03-15 2015-05-07 Cellaegis Devices, Inc. Gas Powered System for Performing Remote Ischemic Conditioning
WO2015006828A1 (en) * 2013-07-17 2015-01-22 Hts Therapeutics Pty Ltd A method for treating haemorrhage, shock and brain injury
US10517892B2 (en) * 2013-10-22 2019-12-31 Medtronic Minimed, Inc. Methods and systems for inhibiting foreign-body responses in diabetic patients
US20150148739A1 (en) * 2013-11-27 2015-05-28 April Marie Radicella Simplified Microplegia Delivery System
US11974568B2 (en) 2020-03-20 2024-05-07 The Cleveland Clinic Foundation Portable, ex vivo, normothermic limb perfusion machine
US12419850B1 (en) 2024-03-21 2025-09-23 GanD, Inc. Bioactive fluid compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002528407A (ja) * 1998-10-23 2002-09-03 ポリヒール リミテッド 創傷治療用のミクロスフェアを含む組成物
JP2002539224A (ja) * 1999-03-23 2002-11-19 ジェームス・クック・ユニバーシティー 臓器の停止、保護、及び保存
US20050176763A1 (en) * 2003-10-14 2005-08-11 Boy Kenneth M. 3-Thia-4-arylquinolin-2-one potassium channel modulators
JP2006514056A (ja) * 2002-12-16 2006-04-27 レノビス， インコーポレイテッド ベンズアミド化合物を使用する痛みおよび外傷性傷害の処置方法ならびにベンズアミド化合物を含有する組成物

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU878297A1 (ru) 1978-05-03 1981-11-07 Научно-Исследовательский Институт Трансплантологии И Искусственных Органов Состав дл сохранени жизнеспособности оперируемого сердца
US4798824A (en) * 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5006512A (en) 1987-10-02 1991-04-09 Tsuyoshi Ohnishi Therapeutic usages of inhibitors for a potassium efflux channel
US5256770A (en) * 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
DE3926287A1 (de) 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5145771A (en) * 1990-04-12 1992-09-08 The University Of North Carolina At Chapel Hill Rinse solution for organs and tissues
US5206222A (en) 1991-05-22 1993-04-27 Vanderbilt University Methods for the reduction of myocardial reperfusion injury
CN1057192A (zh) 1991-06-30 1991-12-25 汪庆富 风油精聚胺酯海绵的制备工艺
US5407793A (en) * 1991-10-18 1995-04-18 University Of Pittsburgh Of The Commonwealth System Of Higher Education An aqueous heart preservation and cardioplegia solution
RU2025973C1 (ru) * 1992-02-10 1995-01-09 Научно-производственное предприятие "Биофарм" Раствор для консервации живых органов
US5370989A (en) * 1992-04-03 1994-12-06 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5405742A (en) * 1993-07-16 1995-04-11 Cyromedical Sciences, Inc. Solutions for tissue preservation and bloodless surgery and methods using same
US5679706A (en) * 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
US5554497A (en) * 1994-12-12 1996-09-10 Charlotte-Mecklenburg Hospital Authority Cardioplegic solution for arresting an organ
US5656420A (en) * 1995-02-24 1997-08-12 University Of Kentucky Research Foundation Method for employing the delta opioid dadle to extend tissue survival time during ischemia
JP3875295B2 (ja) 1995-11-30 2007-01-31 功 竹内 心筋保護液
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
IT1297886B1 (it) 1997-02-28 1999-12-20 Carmine Antropoli Nifedipina per uso topico
CA2295195C (en) * 1997-06-18 2009-12-15 Discovery Therapeutics, Inc. Compositions and methods for preventing restenosis following revascularization procedures
CN1057192C (zh) 1997-09-10 2000-10-11 上海长征医院 一种配制多器官保存液的方法
US6011017A (en) * 1998-04-15 2000-01-04 Cypros Pharmaceutical Corp. Method of reducing pulmonary hypertension and atrial fibrillation after surgery using cardiopulmonary bypass
US7700122B1 (en) 1998-07-16 2010-04-20 Memorial Sloan-Kettering Cancer Center Topical compositions comprising an opioid analgesic and an NMDA antagonist
KR100269540B1 (ko) * 1998-08-28 2000-10-16 윤종용 웨이퍼 상태에서의 칩 스케일 패키지 제조 방법
US6358208B1 (en) * 1998-11-21 2002-03-19 Philipp Lang Assessment of cardiovascular performance using ultrasound methods and devices that interrogate interstitial fluid
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
WO2001054679A2 (en) 2000-01-27 2001-08-02 Children's Hospital Research Foundation Transdermal composition containing an anesthetic and a vasodilator agent
JP2001261575A (ja) 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
US6569615B1 (en) * 2000-04-10 2003-05-27 The United States Of America As Represented By The Department Of Veteran's Affairs Composition and methods for tissue preservation
EP1276475A2 (en) 2000-04-28 2003-01-22 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
EP1324709B1 (en) 2000-09-26 2006-07-12 Medtronic, Inc. Medical device for directing blood flow
EP1478660A4 (en) 2002-01-29 2005-02-09 Cognetix Inc KAPPA-PVIIA-RELATED CONOTOXINS AS ORGAN PROTECTIVE AGENTS
NZ536001A (en) 2002-04-18 2006-05-26 Cv Therapeutics Inc Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside
AUPS312602A0 (en) * 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US20040229780A1 (en) * 2002-09-20 2004-11-18 Olivera Baldomero M. KappaM-conopeptides as organ protectants
US6921633B2 (en) 2002-11-18 2005-07-26 Biolife Solutions Incorporated Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
CA2551169A1 (en) * 2002-12-23 2004-07-08 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery
GB2436255B (en) 2002-12-23 2007-11-28 Global Cardiac Solutions Pty L Organ preconditioning, arrest, protection, preservation and recovery
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
AU2004245484A1 (en) 2003-06-02 2004-12-16 Georgetown University Neuroprotective benzoate and benzamide compounds
EP1827298A4 (en) 2004-12-22 2011-09-28 Univ Emory THERAPEUTIC APPARATUS FOR IMPROVING THE PROTECTIVE EFFECTS OF POST-CONDITIONING ORGANS
WO2007030198A2 (en) 2005-07-11 2007-03-15 Human Biosystems Improved methods and solutions for storing donor organs
KR101425579B1 (ko) 2006-05-29 2014-08-13 하이버네이션 테라퓨틱스 리미티드 개선된 조직 유지법
EP2139316B1 (en) 2006-07-25 2015-03-18 Hibernation Therapeutics, a KF LLC Trauma therapy
US20100119554A1 (en) 2007-03-02 2010-05-13 Hibernation Therapeutics Limited Transplants
CN100423638C (zh) 2007-03-22 2008-10-08 南京吉脉生物技术有限公司 一种器官保存液及其制备方法
JP2010534208A (ja) 2007-07-25 2010-11-04 ハイバーネイション セラピューティクス リミテッド 改善された臓器の保護、保存および回復

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002528407A (ja) * 1998-10-23 2002-09-03 ポリヒール リミテッド 創傷治療用のミクロスフェアを含む組成物
JP2002539224A (ja) * 1999-03-23 2002-11-19 ジェームス・クック・ユニバーシティー 臓器の停止、保護、及び保存
JP2006514056A (ja) * 2002-12-16 2006-04-27 レノビス， インコーポレイテッド ベンズアミド化合物を使用する痛みおよび外傷性傷害の処置方法ならびにベンズアミド化合物を含有する組成物
US20050176763A1 (en) * 2003-10-14 2005-08-11 Boy Kenneth M. 3-Thia-4-arylquinolin-2-one potassium channel modulators

Also Published As

Publication number Publication date
JP2014065724A (ja) 2014-04-17
IL196702A0 (en) 2009-11-18
KR20090047489A (ko) 2009-05-12
ES2539762T3 (es) 2015-07-03
CN103495173B (zh) 2016-11-23
CN101516185A (zh) 2009-08-26
SG173404A1 (en) 2011-08-29
CN103495173A (zh) 2014-01-08
EP2139316A4 (en) 2012-04-25
US9125929B2 (en) 2015-09-08
CA2692256A1 (en) 2008-01-31
US20130190264A1 (en) 2013-07-25
KR101490836B1 (ko) 2015-02-09
KR20140108346A (ko) 2014-09-05
ZA200901376B (en) 2015-12-23
AU2007278754B2 (en) 2014-11-13
US20090324748A1 (en) 2009-12-31
CA2692256C (en) 2017-01-10
AU2007278754A1 (en) 2008-01-31
EP2139316A1 (en) 2010-01-06
EP2139316B1 (en) 2015-03-18
JP5833618B2 (ja) 2015-12-16
WO2008011670A1 (en) 2008-01-31
US20160051572A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
JP5833618B2 (ja) 外傷治療
JP2009544628A5 (enExample)
JP2014196351A (ja) 改善された臓器の保護、保存および回復
JP2010534208A5 (enExample)
US10251905B2 (en) Tissue maintenance
HK1193048A (en) Trauma therapy
CN101500409A (zh) 改善的组织维持
JP2013234200A (ja) 組織維持の改善
HK1147645A (en) Improved organ protection, preservation and recovery
HK1172794A (en) Improved tissue maintenance
HK1190877A (en) Improved tissue maintenance

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130729

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20131129

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131210

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20140107

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140110